Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810458 · ClinicalTrials.gov registry record
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 109
- Enrollment target
NCT01810458 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 109 participants.
The verdict
NCT01810458 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
Interventions
- PROCEDURE Blood draw
- DEVICE Abdominal ultrasound
- PROCEDURE History and physical
- PROCEDURE Intravenous catheter
- OTHER Liver questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2013-10 |
| Est. Completion | 2019-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01810458
The ClinicalTrials.gov registry entry for NCT01810458 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT01810458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01810458 about?
NCT01810458 is a clinical study titled "Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)". We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
What is the current status of trial NCT01810458?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2013-10. Estimated completion is 2019-09.
What interventions are being tested in trial NCT01810458?
The interventions under investigation include: Blood draw (PROCEDURE), Abdominal ultrasound (DEVICE), History and physical (PROCEDURE), Intravenous catheter (PROCEDURE), Liver questionnaire (OTHER).
Who is sponsoring clinical trial NCT01810458?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.